Objective: Several genetic polymorphisms determine vitamin D status. We aimed to estimate the strength of association of established 25-hydroyxvitamin D (25OHD)-associated variants in the mother and in the fetus, with 25OHD concentration in newborn umbilical cord plasma.
M aternal vitamin D deficiency has been associated with obstetric complications and neonatal health, and may have consequences for the fetal immune system (1, 2) . Severe perinatal vitamin D deficiency may affect bone formation in the early neonatal period (3), although it is unclear whether maternal vitamin D directly affects fetal bone formation (4) . It has been hypothesized that vitamin D status in early life may also have consequences for longer term health (5) .
Low concentrations of vitamin D in pregnancy are common in low-and high-income countries at all latitudes (6, 7) . Dietary intake in pregnancy is frequently lower than recommended (8, 9) ; two-thirds of the participants in our cohort study had a daily intake lower than the national recommendation of 10 mg/d (10) .
The main sources of vitamin D are endogenous conversion of 7-dehydrocholesterol (7-DHC) in the skin upon ultraviolet (UV) irradiation and dietary intake of vitamin D. These inactive forms are transported mainly bound to vitamin D-binding protein (DBP) to the liver for hydroxylation by 25-hydroxylase (CYP2R1) to 25-hydroxyvitamin D (25OHD), which is the stable form of vitamin D and a biomarker for vitamin D status. Further hydroxylation produces the bioactive hormone, 1,25(OH) 2 D. The first step in catabolism and excretion of vitamin D is hydroxylation by 24-hydroxylase (CYP24A1).
It is now established from large genomewide association and other studies that the main genetic predictors of circulating 25OHD in adults are polymorphisms in the GC gene encoding DBP, near the genes encoding for vitamin D hydroxylation (CYP2R1 and CYP24A1) as well as the gene encoding 7-DHC reductase (DHCR7) (11) (12) (13) (14) . The 7-DHC reductase catalyses the conversion of 7-DHC to cholesterol and is thought to influence vitamin D synthesis via substrate supply (15) .
The mechanisms underlying placental transfer and fetal vitamin D acquisition are not fully understood. It is thought that maternal 25OHD crosses the placenta, whereas 1,25(OH) 2 D does not (1, 4) . It is well known that a higher maternal 25OHD and dietary vitamin D supplementation results in higher neonatal 25OHD (1) . If the fetus relies on maternal supply of 25OHD, the previously mentioned genetic associations raise an interesting question (as illustrated in Supplemental Fig. 1 ): Because the fetus is not exposed to UV irradiation, and most likely does not obtain substantial quantities of nonhydroxylated vitamin D from the mother, would the fetal CYP2R1 and DHCR7 genotype influence cord blood 25OHD?
To our knowledge, no previous study has assessed the influence of fetal and maternal vitamin D genotype on neonatal 25OHD. We hypothesized that maternal genetic variants are more important than fetal ones in predicting cord blood 25OHD.
Subjects and Methods

Cohort description and selection of cases
The Norwegian Mother and Child cohort study (MoBa) is a prospective population-based pregnancy cohort study conducted by the Norwegian Institute of Public Health recruiting pregnant women across Norway between 1999 and 2008; 41% of eligible women participated (16) . The current study is based on analyses of maternal samples and cord blood and data from repeated questionnaires from pregnancy and the national birth registry. The Norwegian Data Protection Authority and The Regional Committee for Medical Research Ethics have approved the establishment and data collection in MoBa. Written informed consent was obtained from all study participants.
From the MoBa cohort (n = 113,053 children), we randomly selected 1009 mother and child dyads, of which 578 had available biobanked samples (Fig. 1, flowchart) . Baseline characteristics for those with available blood samples were largely similar to that in the whole cohort, except for a lower proportion with preterm birth and delivered by cesarean section among participants with blood samples (Supplemental Table 1 ). The study was part of a nested case-cohort study on type 1 diabetes and celiac disease in childhood. Concentrations of 25OHD were similar among cases and the random sample (17; unpublished data), and we therefore used the independent sample of 594 cases to replicate our main results (baseline characteristics shown in Table 1 ).
Blood sampling
Maternal blood samples were collected in EDTA tubes at hospital laboratories at enrollment around week 18 of pregnancy and again soon after delivery (0 to 7 days postpartum; median, 1 day). Plasma was separated before shipment overnight to the MoBa Biobank. Immediately after birth, an umbilical cord blood sample was collected, shipped to the biobank, and plasmaseparated upon arrival. All samples were stored at 280°C until analysis (18) .
Laboratory assays
Statens Serum Institut (Copenhagen, Denmark), a laboratory internationally certified by the Vitamin D External Quality Assessment Scheme, analyzed plasma 25OHD 3 and -D 2 using a liquid chromatography tandem mass spectrometer (from Thermo, Waltham, MA). The lower level of quantification (LLOQ) for 25OHD 3 was 8.5 nmol/L; concentrations below this were set to one-half of the LLOQ Figure 1 . Flowchart of participants in the study. *Pregnancies in which the offspring developed celiac disease or type 1 diabetes.
concentration (4.25 nmol/L). The interassay coefficient of variation for 25OHD 3 , based on repeated measurements of standards with a concentration 33 nmol/L, was 3.4%. For 25OHD 2 , LLOQ was 5.8 nmol/L. Because 99.5% of the samples had a concentrations below this limit, we gave the value zero for 25OHD 2 to these samples. We used the sum of b Missing for 39 of the randomly selected and 25 of the replication sample.
c Missing for 53 of the randomly selected and 38 of the replication sample.
d Missing for 185 of the randomly selected and 174 of the replication sample.
e Missing for 49 of the randomly selected and 43 of the replication sample.
25OHD 2 and 25OHD 3 as the outcome variable, hereafter referred to as 25OHD. In addition to the described laboratory assays, we externally validated 80 blinded study samples from midpregnancy by an independent laboratory (BEVITAL, Bergen, Norway), also using an liquid chromatography tandem mass spectrometer assay (19) . The average difference within samples was 23.0 nmol/L [95% confidence interval (CI), 226.3 to 20.3]; the average between laboratory coefficients of variation was 1.1% (Supplemental Fig. 2 ).
Genotyping assays and genetic risk scores
DNA from maternal and from cord blood was extracted and stored at the biobank. The Core Facility for Genotyping at Oslo University Hospital performed single nucleotide polymorphism (SNP) genotyping using a Custom GoldenGate assay (Illumina, San Diego, CA) per manufacturer's protocol.
We genotyped nine SNPs in or near four genes (CYP2R1, CYP24A1, GC, and DHCR7) associated with vitamin D metabolism (SNPs listed in Supplemental Table 2 ) (11) (12) (13) (14) . For some loci/SNPs, we included several SNPs in strong linkage disequilibrium to account for possible failures in the genotyping and poor genotyping quality. For quality control, we required a genotype success rate of .80%, Hardy-Weinberg equilibrium with P , 0.01, and no aberrant clustering (assessed by visual inspection). We assessed the prediction of maternal 25OHD by individual SNPs in our dataset per maternal risk allele (Supplemental Table 2 ) (11, 13) .
The three subtypes of the DBP (DBP1S, DBP 1F, and DBP 2) are characterized by the GC SNPs rs4588 and rs7059. We used the SNP rs2282679 as a proxy for rs4588 and rs222040 for rs7059 because they are in strong linkage disequilibrium (r 2 . 0.99 in European populations) (20, 21) .
Finally, four SNPs were retained to calculate a vitamin D deficiency genotype risk score (GRS): SNPs within a single gene were checked for linkage disequilibrium (LD) and removed if correlated (r 2 . 0.05) (21) . We chose between SNPs in LD by assessing quality (success rate, cluster assessment) and, if there were no substantial differences, selected the most commonly used in the literature. Two SNPs were selected based on prediction in maternal samples in our dataset (Supplemental Table 2 ; rs2282679 for GC and rs12785878 for DHCR7). Additionally two SNPs were retained based on previous literature (rs10741657 for CYP2R1 and rs6013897 for CYP24A1) (11-13).
Dietary intake of vitamin D
Participants completed a food frequency questionnaire in midpregnancy, which also included use of dietary supplements (22) . Total dietary intake from foods and supplements has been validated against a 4-day food diary and biomarkers (22, 23) . We divided the total intake of vitamin D from food and supplements in quartiles.
Other variables
We retrieved information from the Medical Birth Registry on sex, birth weight, gestational age, maternal age, mode of delivery, geographical region of living (north, mid/west, and south-east) and month and year of birth. From the MoBa questionnaire at recruitment approximately in gestational week 18, we obtained prepregnant body mass index (BMI; kg/m 2 ), smoking during pregnancy, maternal education, and origin (indicated by whether maternal first tongue is Norwegian).
Statistical methods
Our primary analysis focused on studying genetic predictors for concentrations of 25OHD in cord blood. To accomplish this, we first assessed the effect of seasonal variation by month of sampling on 25OHD. Because of the well-established seasonal variation in plasma 25OHD concentration, we used season-adjusted (deseasonalized) concentrations to study other environmental and genetic factors (24) . We corrected for season (month of year) at time of blood sample collection by modeling sine cosine functions (cosinor model) for seasonal variation (25) . In essence, the average season-specific deviation from the overall (yearly) mean is added to the observed 25OHD concentration, so that concentrations measured in samples collected during the peak season are adjusted down and concentrations measured in samples collected during late winter are adjusted up to provide the best possible estimate. The average seasonal means were obtained from linear regression models with a sine and cosine function of radians as described, for instance, by Barnett et al. (25) .
The proportion of variance explained (R 2 ) by each predictor tested was determined in simple linear regression analyses. Finally, we estimated the total associations for all predictors without season-adjustment in a multivariable regression model. We used Stata (V14, StataCorp., College Station, TX) for the statistical analyses.
Results
In the randomly selected sample, mean cord plasma 25OHD was 35.2 nmol/L (95% CI, 33.6 to 36.8) compared with 59.4 nmol/L (95% CI, 57.4 to 61.5) in midpregnancy and 49.5 nmol/L (95% CI, 47.4 to 51.7) in maternal postdelivery samples. The maternal postdelivery and cord blood levels for 25OHD were closely correlated (Spearman's rho = 0.77, P , 0.001). The difference between cord and maternal postdelivery samples (mean, 14.2; 95% CI, 12.8 to 15.6) was significantly lower at low maternal 25OHD concentrations (P , 0.0001, Supplemental Fig. 3 ).
Maternal genetic variants predicting maternal 25OHD
For maternal 25OHD concentrations, a maternal GRS including four SNPs could explain 3.0% of the variance. We found the strongest association with maternal genotypes at SNPs in the GC gene (rs2282679, rs1352846, and rs222040). Two SNPs for the DHCR7 gene (rs12785878 and rs3829251) were also important predictors for 25OHD (Supplemental Table 2 ). Because the SNPs for each of these genes did not meet the requirements for LD, only rs2282679 and rs12785878 were retained in further analyses.
Maternal and fetal genetic variants predicting cord plasma 25OHD
Fetal GRS accounted for 3.3% of the total variation in fetal 25OHD concentrations and maternal GRS for 2.1% (Table 2 ). These findings in the combined sample cohort were similar in the random and replication samples separately. With fetal and maternal GRS as independent predictors in a regression model, only fetal GRS remained significantly associated with cord blood 25OHD (change, 1.6 nmol/L per 25OHD-increasing allele; 95% CI, 0.6 to 2.5).
The maternal SNP in GC predictive for maternal 25OHD was also weakly associated with cord plasma 25OHD. However, the associations for the corresponding fetal SNP with cord plasma 25OHD were considerably stronger (combined sample in Table 3 ; shown separately in Supplemental Table 3 ). The association for fetal SNPs with 25OHD did not change substantially with adjustment for maternal SNPs. Conversely, after adjustment for fetal SNPs, the maternal SNPs were not associated with cord plasma 25OHD (Table 3) .
For the DHCR7 SNP, the associations for maternal and fetal variants with cord blood 25OHD were of similar magnitude, and both remained significant predictors in adjusted analyses (Table 3) .
Environmental predictors for cord plasma 25OHD
In the combined sample, season of birth was the strongest predictor for cord plasma 25OHD, with a peak in August (mean, 50.2 nmol/L) and a nadir from February to April (24.9 to 25.4 nmol/L). Season of sampling explained 19.5% of the total variance in cord 25OHD (Supplemental Table 4 ). After adjusting for seasonal variation, maternal dietary intake (3.3 nmol/L increase per quartile, R 2 = 0.044) and prepregnancy BMI (0.6 nmol/L decrease per increase of kg/m 2 , 3.1 nmol/L decrease per increase in BMI category, R 2 = 0.020) were significant predictors. Geographical region of living was associated with 25OHD, and maternal age was significant in unadjusted but not in adjusted analyses (Table 4 and Supplemental Table 4 ). The concentrations were not associated with year of birth, which also reflects the storage time (Supplemental Table 4 ).
Overall, in a multiple regression model, season, maternal dietary intake and age, prepregnancy BMI, geographical region of living, and fetal genotype explained 28.3% of the total variance in cord plasma 25OHD (Table 4 ).
Discussion
Our finding was that fetal genetic variants predicted newborn vitamin D status independently of the respective maternal variants. The maternal genetic variants were not independent predictors of neonatal 25OHD. The results did not support our hypothesis that maternal are more important than fetal variants, and this raises intriguing questions about how fetal genetic variants influence cord 25OHD.
To our knowledge, no previous study has estimated the association of both maternal and fetal 25OHD-associated SNPs with cord blood or neonatal 25OHD. However, one recent Australian study found that fetal 25OHD-associated SNPs in GC and DHCR7 predicted 25OHD concentration in neonatal dried blood spots, in accordance with our findings (26) . In that study, a potential confounding by the corresponding maternal SNPs could not be assessed. In our study, the corresponding maternal SNPs were also associated with cord plasma 25OHD, but not after controlling for fetal genotype. Our findings suggest that the association of maternal genotype with cord blood 25OHD is mediated, at least in part, through the fetal genotype.
The prediction of maternal 25OHD by the maternal GRS in terms of proportion of variance explained in our study (R 2 = 3.0%) was comparable to a study including nonpregnant men and women of European ancestry from a Number of 25OHD-increasing alleles across the four SNPs: rs10741657, rs6013897, rs2282679, and rs12785878.
five countries (R 2 = 2.8%) (12) . Compared with the prediction within the mother, we found that the total variation in 25OHD explained by genetic factors in the fetus was similar (R 2 = 3.3%). The SNP rs2282679 for GC separates the two main isoforms of DBP, traditionally called DBP1 and DBP2 (20) . Individuals homozygous for the major allele encoding for the DBP1 isoform have higher concentrations of 25OHD, whereas heterozygotes have an intermediate concentration (27) . The SNP rs222040 further separates DBP1 into two isoforms, DBP1F and DBP1S, differing by a single amino acid. In our study, the two GC SNPs in both the mother and the fetus predicted cord 25OHD, but only the fetal GC SNPs remained significant when fetal and maternal SNPs were mutually adjusted for each other.
DBP is thought to prolong the half-life of plasma 25OHD (28) . DBP1 has a higher affinity compared with DBP2 for binding with 25OHD (29) . Differences in DBP structure and affinity for 25OHD may also indirectly influence concentrations of 25OHD during fetal life. DBP is expressed in the placenta, but whether maternal and fetal DBP is involved in placental vitamin D transfer is not known (20) . 7-DHC is the precursor of both previtamin D 3 and cholesterol, and the enzyme DHCR7 catalyzes conversion of 7-DHC to cholesterol (15) . The nonenzymatic conversion of 7-DHC to previtamin D 3 is facilitated by exposure to UV light. The role of the polymorphisms of DHCR7 was discovered by two independent groups in 2010 (11, 12) . It is thought that DHCR7 may regulate 25OHD production in the skin by controlling availability of 7-DHC, but the functional consequences of the 25OHD-associated SNPs near DHCR7 are not known in any molecular detail (15) . A causal role of genetic variants near DHCR7 is indirectly supported by strong signs of positive selection for the DHCR7 alleles and haplotypes associated with higher 25OHD, resulting in higher frequencies of these alleles in European populations than in African and Asian populations (30) . At any rate, it remains a mystery how fetal variants near DHCR7 can influence cord 25OHD, because the fetal skin is not exposed to UV light and would therefore not be expected to produce previtamin D from 7-DHC.
We may speculate that fetal endogenous vitamin D synthesis may differ from that in adults, and that 7-DHC may somehow be converted to previtamin D and vitamin D in the fetus or the placenta, but this warrants further research if our and the results from the Australian study are confirmed (26) . If this is the case, fetal or placental 25-hydroxylase would also be required for the fetus to obtain own 25OHD. The placental genotype, identical to the fetal, may be important for fetal vitamin D acquisition. Further, it would be expected that the fetal CYP2R1 genotype would be associated with 25OHD, as documented for adults, but this was not seen in our study or in the Australian study (26) .
The current study had limited sample size to study gene variants with weaker effects, as illustrated by the nonsignificant association for previously confirmed maternal CYP2R1 SNPs and 25OHD. However, our main findings were replicated in an independent sample of similar size. The independent role of fetal DHCR7 and GC SNPs in predicting newborn 25OHD nevertheless warrants replication in other cohorts and further study of potential mechanisms involved. Furthermore, studies including the effects of paternal alleles and nontransmitted maternal alleles would add information to our understanding of fetal vitamin D acquisition.
The association of season of birth, maternal vitamin D intake, and maternal prepregnant BMI with 25OHD in our study was consistent with several other studies (7, 31) . We did not find any association of cord 25OHD and sample storage time, likely because our samples were plasma stored at 280°C in contrast to dried blood spots (26) .
To conclude, we showed that the fetal genotypes for vitamin D metabolism were more important than maternal genotypes. If confirmed in other studies, this raises interesting questions about placental transfer of maternal 25OHD and calls for further investigations of how the fetus acquires vitamin D.
